Clinical Trials Browser

Phase 1 × NVP-BKM120 × Breast × Clear all

NCT01623349 2021-02-10

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Phase 1 Completed

118 enrolled

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Recurrence

NCT01576666 2020-12-19

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Phase 1 Completed

120 enrolled

BreastCNSGastrointestinal

Breast Neoplasms, Glioblastoma, Stomach Neoplasms, Colorectal Neoplasms

NCT02154776 2020-12-19

LeeBLet

Phase 1 Completed

13 enrolled

Breast

Breast Neoplasms

NCT02088684 2020-12-17

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Phase 1 Completed

70 enrolled

Breast

Breast Neoplasms

NCT01155453 2020-12-09

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Phase 1 Completed

113 enrolled

BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01626209 2020-12-09

A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms

NCT01068483 2020-12-08

Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients

Phase 1 Completed

107 enrolled

BreastGastrointestinalGynecologic

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT01363232 2020-10-05

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

Phase 1 Completed

89 enrolled

BreastGastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT02058381 2020-03-09

B-YOND

Phase 1 Completed

40 enrolled

Breast

Pre-menopausal Breast Cancer

NCT01339442 2017-01-25

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

Phase 1 Completed

31 enrolled

Breast

Breast Neoplasms

NCT01248494 2016-07-25

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

Phase 1 Completed

72 enrolled

Breast

Breast Neoplasms